» Non-Financial

Company Directors
Company Advisors
New & Press Releases
Directors Share Dealings
Major Shareholders
Company Subsidiary Calendar of Future Events
Company Name Change
Company Status Change

» Analyst Spreadsheet

Quick View(PDF)
Trader(PDF)
Dossier(PDF)
Download Analyst Template
Analyst Spreadsheet
Download Master Template
Annual Master Spreadsheet
Quarterly Master Spreadsheet
Annual & Quaterly Master Spreadsheet
Valuation Model Template
Valuation Model Spreadsheet
Business Risk(PDF)
Credit Metrics(PDF)
Annual Reports

For all products and/or service inquiries or to learn more about how WVB customer service solutions can reduce your service costs while increasing customer satisfaction, email us at .

GENEMATRIX

WVB Number : KOR000040597 Country : Republic of Korea
SIC categorization : COML PHYSICAL, BIOLOGCL RESH (8731) ISIN : KR7109820001
FT categorization : DIV'D HEALTH & PERSONAL CARE (430)  
Company status: ACTIVE  

» Corporation Profile :

Profile in brief:
The Company is a Korea-based biotechnology company. The Company mainly develops restriction fragment mass polymorphisms (RFMP) clinical diagnostic systems, RFMP molecular markers, human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) theranostics systems, molecular diagnostic platforms, and systems for microorganism identification.
Phone : 82 031 628 2000 Fax : 031 628 2002
Chairman: : N/A Auditor : SAMIL PRICEWATERHOUSE COOPERS
CEO/Managing Director : WANG DON YOO

» Company Facts

Net Profit Margin (%) -28.32  
Operating Margin (%) -31.55  
Return on Assets (%) -7.93  
Return on Equity (%) -11.51  
Employees 15  

» Company Financials

  Annual (2017)
Income Statement
('000 KRW )
Sales/Total Revenue 5,189,163  
EBITDA -1,431,650  
EBIT -1,762,136  
Net Income -1,469,764  
Balance Sheet
( '000 KRW)
Total Current Assets 11,080,946  
Total Assets 17,743,477  
Current Liabilities 5,025,483  
Total Liabilities & Debt 5,798,348  
Total Equity 11,945,129  
Cash & Flow
( '000 KRW)
Net Income/Staring Line -1,734,513  
Cash from Operating -1,773,701  
Cash from Investing 1,726,614  
Cash from Financing 90,879  
Cash & Equivalent Yr End 1,262,785